drugset
drugset / Trial / NCT04418167

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167 ↗

Phase 1 Suspended 71 enrolled JS InnoPharm, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

Timeline

Start
2020-06-18
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabrafenib Small molecule — Oral
Subject JSI-1187 Unknown 2 mg Oral
Subject JSI-1187 Unknown 4 mg Oral
Subject JSI-1187 Unknown 8 mg Oral
Subject JSI-1187 Unknown 16 mg Oral
Subject JSI-1187 Unknown 24 mg Oral
Subject JSI-1187 Unknown 36 mg Oral
Subject JSI-1187 Unknown 56 mg Oral
Subject JSI-1187 Unknown 88 mg Oral
Subject JSI-1187 Unknown 128 mg Oral

Indications

cancer